Core Insights - Perfect Corp. (NYSE: PERF) reported Q4 and FY 2024 results, leading to a negative market reaction with shares declining by 4 to 5% following the announcement [1] Financial Performance - The company released its financial results before the market opened on February 26th, indicating a significant event for investors [1] Market Reaction - The immediate market response to the earnings report was unfavorable, resulting in a drop in stock price [1]

Group 1 - The article provides an overview of Coinbase's business areas and discusses their potential impact on the company's future [1] - The author has a long position in Coinbase shares, indicating a positive outlook on the stock [2] - The article is part of a deep research process before making investment decisions, suggesting a thorough analysis of the company's fundamentals [1] Group 2 - The author emphasizes that a "hold" recommendation implies that the stock should not be traded, as there are perceived better investment opportunities available [1]

Group 1: Nuclear Energy and Uranium Demand - The growing interest in nuclear energy is driving a bullish outlook for uranium, particularly as tech giants seek reliable energy sources for AI data centers [1] - The Trump administration is expected to support policies that position uranium as a critical mineral for nuclear power, potentially leading to federal subsidies for uranium mining projects [2][3] - Uranium demand is projected to rise significantly, with the World Nuclear Association estimating a 28% increase in reactor demand by 2030 and nearly doubling by 2040 [12] Group 2: Investment Initiatives and Economic Impact - President Trump announced a $500 billion private-sector investment initiative called "Stargate," aimed at building AI infrastructure, starting with a $100 billion investment in a Texas data center [6] - Tech giants have committed over $1 trillion to U.S. investments, with Apple pledging $500 billion over four years, focusing on AI server production and creating approximately 20,000 jobs [8] - Meta plans to invest $65 billion in AI-focused projects by 2025, including data center construction, while Microsoft aims to invest over $40 billion in U.S. data centers [9] Group 3: Uranium Price Forecasts - Bank of America forecasts a price surge of over 50% for uranium, predicting it will reach $120 per pound this year, with further increases to $135 in 2026 and $140 in 2027 [11] - Current uranium prices are well below last year's peak, presenting a buy-the-dip opportunity for investors as demand grows and supply constraints persist [12] - Tariffs introduced by President Trump could further support rising uranium prices, with estimates suggesting a potential 10% increase due to Canadian tariffs [14][15] Group 4: Investment Opportunities in Uranium ETFs - Uranium ETFs are considered appealing for long-term investment as demand surges due to the push for nuclear energy to power data centers [16] - Recommended ETFs include Global X Uranium ETF (URA), VanEck Uranium+Nuclear Energy ETF (NLR), and Sprott Junior Uranium Miners ETF (URNJ), among others [17] - URA has the largest asset base of $3.31 billion and is the most liquid option, while URAN is the cheapest in terms of annual fees, making it suitable for long-term investing [18]

Core Viewpoint - Regeneron Pharmaceuticals has experienced a significant decline in stock price, down 18.9% for 2024, but has recently rebounded from three-year lows following its Q4 earnings report, which showed positive financial results and the initiation of a dividend [3][4][9]. Financial Performance - Regeneron reported Q4 2024 EPS of $12.07, exceeding consensus estimates by $0.71, with revenues increasing 10.3% year-over-year to $3.79 billion, surpassing analyst expectations of $3.74 billion [9]. - Non-GAAP net income rose 2% year-over-year to $1.39 billion, and collaboration revenue from Sanofi increased to $3.924 billion from $3.127 billion [9]. - The company initiated its first-ever dividend of $0.88 and expanded its stock buyback program by an additional $3 billion, totaling $4.5 billion [4][9]. Key Products and Market Position - Dupixent, Regeneron's leading product, generated $14.15 billion in sales for 2024, reflecting a 22% year-over-year growth [6]. - Eylea, another significant product, generated $5.9 billion in the U.S. but saw only a 1% increase in sales year-over-year, indicating a slowdown in growth [7]. - Libtayo, a newer product, experienced a 40% year-over-year sales increase to $1.22 billion, showing potential for future growth [7]. Future Outlook - Regeneron is seeking FDA approval to expand Dupixent's use, which could potentially add 300,000 new patients in the U.S. alone [6]. - The company has guided for a non-GAAP gross margin on net product sales between 87% to 88% for 2025, with R&D expenses projected between $5 billion and $5.2 billion [10]. - The stock has a 12-month price forecast averaging $973.13, with a potential upside of 37.65% based on analyst ratings [9][12]. Technical Analysis - Regeneron stock is attempting to form a cup and handle pattern, indicating a potential bullish breakout if it exceeds previous highs [10][11]. - The stock has shown signs of recovery after hitting a three-year low, with key Fibonacci support levels identified [11].

Perfect Corp. (NYSE:PERF) Q4 2024 Earnings Call February 26, 2025 7:30 PM ET Company Participants Jimmy Xia - Investor Relations Alice Chang - Founder, Chairwoman and Chief Executive Officer Louis Chen - Executive Vice President and Chief Strategy Officer Iris Chen - Vice President, Finance and Accounting Conference Call Participants Pat McCann - Noble Lisa Thompson - Zacks Investment Research Aashi Shah - Sidoti Operator Good morning and good evening, ladies and gentlemen. Thank you for standing by and wel ...

Exhibit 99.1 Perfect Corp. Reports Unaudited Financial Results for the Three Months and Full Year Ended December 31, 2024 New York – February 26, 2025 – Perfect Corp. (NYSE: PERF) ("Perfect" or the "Company"), a global leader in providing artificial intelligence ("AI") and augmented reality ("AR") Software-as-a-Service ("SaaS") solutions to beauty and fashion industries, today announced its unaudited financial results for the three months and the full year ended December 31, 2024. Highlights for the Three M ...

Core Insights - The individual has retired after over 43 years in investment research, now operating independently to provide actionable investment insights [1] - The focus is on rules and factor-based equity investing strategies, emphasizing the use of numbers to inspire human intelligence-driven investment narratives [1] - The approach combines quantitative analysis with classic fundamental analysis to uncover the true story of companies and their stocks, aiming to predict future performance [1] Investment Strategy - The individual has extensive experience covering a wide range of stocks, including large cap, small cap, micro cap, value, growth, and special situations [1] - Previous roles included managing a high-yield fixed-income fund and conducting research on quantitative asset allocation strategies, which are foundational to modern Robo Advising [1] - The individual has authored two books on stock selection and analysis, showcasing a commitment to investor education [1] Future Outlook - The new phase on Seeking Alpha aims to provide valuable insights, with an open invitation for feedback from the audience [1] - The individual expresses a willingness to engage with criticism, indicating a focus on continuous improvement in delivering investment insights [1]

Core Viewpoint - JPMorgan's shares have reached an all-time high, reflecting strong market performance and positive investor sentiment, with a year-to-date increase of 15.4% [1] Group 1: Stock Performance - JPMorgan's stock closed at $279.23, marking a significant rise compared to its peers, with Citigroup up 20.2% and Bank of America up 6.9% this year [1] - The stock has outperformed the industry average growth of 13.4% and the S&P 500's growth of 3.9% [1] Group 2: Financial Indicators - Technical indicators show that JPMorgan is trading above its 50-day and 200-day moving averages, indicating a bullish trend [3] - The company's net interest income (NII) is projected to reach nearly $94 billion in 2025, up from $93 billion in 2024, driven by a high-interest rate environment [8] Group 3: Capital Markets and Investment Banking - JPMorgan's capital markets business is recovering, with investment banking fees increasing by 37% year-over-year, following previous declines [9] - The company expects markets revenues to contribute approximately $4 billion to firm-wide NII this year, a significant increase from $1 billion in 2024 [10] Group 4: Expansion and Acquisitions - JPMorgan has been actively pursuing acquisitions, including increasing its stake in Brazil's C6 Bank and acquiring the failed First Republic Bank, which has positively impacted its financials [13][14] - The company plans to open over 500 branches and renovate around 1,700 locations by the end of 2027, enhancing its retail banking presence [15] Group 5: Asset Quality and Challenges - JPMorgan's asset quality has been declining, with provisions increasing significantly over the past few years due to a challenging macroeconomic environment [21] - The mortgage business has faced challenges due to high mortgage rates, leading to a negative CAGR of 13.6% over the past three years [19] Group 6: Earnings Estimates - Earnings estimates for JPMorgan for 2025 indicate an 8.4% decline year-over-year, primarily due to weakness in the mortgage banking sector and rising non-interest expenses [26] - However, earnings for 2026 are projected to grow by 7.3% [27] Group 7: Valuation and Investor Sentiment - JPMorgan's stock is currently trading at a forward P/E of 15.14X, slightly above the industry average of 14.52X, indicating a premium valuation [30] - Despite the premium valuation, the company's strong market position and strategic growth plans suggest potential for solid long-term returns [32]

Group 1 - The article emphasizes the advantages of a dividend-focused value investment strategy, highlighting capital preservation and steady income growth as key benefits [1] - The author discusses a diversified dividend stock portfolio that prioritizes high-quality value stocks, which are expected to provide meaningful growth and long-term safety [1] Group 2 - The author has disclosed a beneficial long position in shares of specific companies, indicating a personal investment in BF.A, KO, UNLYF, and VFC [2] - The article is presented as a personal opinion and does not constitute investment or tax advice, emphasizing the author's status as a private investor [3]

This is my first coverage of PagSeguro (NYSE: PAGS ). In the article, I will describe PagSeguro's business areas and my opinion on why I think after the recent pullback, the company is undervalued. I will go intoI first entered investing in 2016 as an individual value investor. In 2022, I established the investment firm Libra Capital. I mostly write articles as part of my deep research into a company before I make an investment, whether long or short. For me, a ''hold'' article means don't touch the stock; ...